Abstract:Proteolysis-targeting chimeras (PROTACs) technology has garnered significant attention over the last 10 years, representing a burgeoning therapeutic approach with the potential to address pathogenic proteins that have historically posed challenges for traditional small-molecule inhibitors. PROTACs exploit the endogenous E3 ubiquitin ligases to facilitate degradation of the proteins of interest (POIs) through the ubiquitin–proteasome system (UPS) in a cyclic catalytic manner. Despite recent endeavors to advance the utilization of PROTACs in clinical settings, the majority of PROTACs fail to progress beyond the preclinical phase of drug development. There are multiple factors impeding the market entry of PROTACs, with the insufficiently precise degradation of favorable POIs standing out as one of the most formidable obstacles. Recently, there has been exploration of new-generation advanced PROTACs, including small-molecule PROTAC prodrugs, biomacromolecule-PROTAC conjugates, and nano-PROTACs, to improve the in vivo efficacy of PROTACs. These improved PROTACs possess the capability to mitigate undesirable physicochemical characteristics inherent in traditional PROTACs, thereby enhancing their targetability and reducing off-target side effects. The new-generation of advanced PROTACs will mark a pivotal turning point in the realm of targeted protein degradation. In this comprehensive review, we have meticulously summarized the state-of-the-art advancements achieved by these cutting-edge PROTACs, elucidated their underlying design principles, deliberated upon the prevailing challenges encountered, and provided an insightful outlook on future prospects within this burgeoning field.

Discovery of novel anti-angiogenesis agents. Part 11: Development of PROTACs based on active molecules with potency of promoting vascular normalization

Development of Hybrid Aptamers-Engineered PROTACs for Degrading VEGF165 in Both Tumor- and Vascular Endothelial Cells

New Application of Novel Tetrazine Derivatives As Potent VEGFR-2 Kinase Inhibitors and Anti-Cancer Agents

Discovery of novel VEGFR-2-PROTAC degraders based on the localization of lysine residues via recruiting VHL for the treatment of gastric cancer

VHL-based PROTACs as potential therapeutic agents: Recent progress and perspectives

Design, synthesis, and in vitro and in vivo anti-angiogenesis study of a novel vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitor based on 1,2,3-triazole scaffold

Exploring the potential intracellular targets of vascular normalization based on active candidates

Identification of novel and potent PROTACs targeting FAK for non-small cell lung cancer: Design, synthesis, and biological study

Discovery of novel EGFR-PROTACs capable of degradation of multiple EGFR-mutated proteins

PROTACs: A novel strategy for cancer therapy

Discovery of a Miniaturized PROTAC with Potent Activity and High Selectivity

Design, synthesis, and biological evaluation of potent FAK-degrading PROTACs

Design, synthesis and biological evaluation of indazole derivatives as VEGFR-2 kinase inhibitors with anti-angiogenic properties

New-generation advanced PROTACs as potential therapeutic agents in cancer therapy

Discovery of novel amide derivatives against VEGFR-2/tubulin with potent antitumor and antiangiogenic activity

Innovative Fusion: Natural Compound‐Rhein and PROTACs Unleash Potent VEGFR‐2 Degraders

Design and discovery of new selective and potent VEGF receptor 2 tyrosine kinase inhibitors

Discovery of Potent PROTACs Targeting EGFR Mutants through the Optimization of Covalent EGFR Ligands

An overview of PROTACs: a promising drug discovery paradigm

Discovery of novel protein degraders based on bioorthogonal reaction-driven intracellular self-assembly strategy

PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy